Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/214820
Title: Biomarkers for personalised prevention of chronic diseases: a common protocol for three rapid scoping reviews
Author: Plans Beriso, E.
Babb De Villiers, C.
Petrova, D.
Barahona López, C.
Diez Echave, P.
Hernández, O. R.
Fernández Martínez, N. F.
Turner, H.
García Ovejero, E.
Craciun, O.
Fernández Navarro, P.
Fernández Larrea, N.
García Esquinas, E.
Kuhn, I.
Jiménez Planet, V.
Moreno Aguado, Víctor
Rodríguez Artalejo, F.
Sánchez, M. J.
Pollan Santamaria, M.
Blackburn, L.
Kroese, M.
Pérez Gómez, B.
Keywords: Medicina personalitzada
Malalties neurodegeneratives
Personalized medicine
Neurodegenerative Diseases
Issue Date: 1-Jun-2024
Publisher: Springer Science and Business Media LLC
Abstract: Introduction: Personalised prevention aims to delay or avoid disease occurrence, progression, and recurrence of disease through the adoption of targeted interventions that consider the individual biological, including genetic data, environmental and behavioural characteristics, as well as the socio-cultural context. This protocol summarises the main features of a rapid scoping review to show the research landscape on biomarkers or a combination of biomarkers that may help to better identify subgroups of individuals with different risks of developing specific diseases in which specific preventive strategies could have an impact on clinical outcomes. This review is part of the Personalised Prevention Roadmap for the future HEalThcare (PROPHET) project, which seeks to highlight the gaps in current personalised preventive approaches, in order to develop a Strategic Research and Innovation Agenda for the European Union. Objective: To systematically map and review the evidence of biomarkers that are available or under development in cancer, cardiovascular and neurodegenerative diseases that are or can be used for personalised prevention in the general population, in clinical or public health settings. Methods: Three rapid scoping reviews are being conducted in parallel (February-June 2023), based on a common framework with some adjustments to suit each specific condition (cancer, cardiovascular or neurodegenerative diseases). Medline and Embase will be searched to identify publications between 2020 and 2023. To shorten the time frames, 10% of the papers will undergo screening by two reviewers and only English-language papers will be considered. The following information will be extracted by two reviewers from all the publications selected for inclusion: source type, citation details, country, inclusion/exclusion criteria (population, concept, context, type of evidence source), study methods, and key findings relevant to the review question/s. The selection criteria and the extraction sheet will be pre-tested. Relevant biomarkers for risk prediction and stratification will be recorded. Results will be presented graphically using an evidence map. Inclusion criteria: Population: general adult populations or adults from specific pre-defined high-risk subgroups; concept: all studies focusing on molecular, cellular, physiological, or imaging biomarkers used for individualised primary or secondary prevention of the diseases of interest; context: clinical or public health settings. Systematic review registration: https://doi.org/10.17605/OSF.IO/7JRWD (OSF registration DOI).
Note: Reproducció del document publicat a: https://doi.org/10.1186/s13643-024-02554-9
It is part of: Systematic Reviews, 2024, vol. 13, num. 1
URI: https://hdl.handle.net/2445/214820
Related resource: https://doi.org/10.1186/s13643-024-02554-9
ISSN: 2046-4053
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
s13643-024-02554-9.pdf1.03 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons